[The effect of n-3 fatty acid administration on selected indicators of cardiovascular disease risk in patients with type 2 diabetes mellitus].

Abstract

BACKGROUND:

Serum triacylglycerols (TG), VLDL, HDL, fatty acid and eicosanoid spectrum are among the factors determining the risk of cardiovascular complications in NIDDM. N-3 polyunsaturated fatty acids (PUFA) are expected to have beneficial effects on these factors. In NIDDM patients there have however been previously reported (late 1980s) some adverse effects.

OBJECTIVES:

Our aim was to verify the effects of n-3 PUFA in NIDDM patients using relatively low dosage.

METHODS:

The investigated group included 21 NIDDM patients with dyslipoproteinemia type IV. The patients were treated for 28 days with 1.7 g EPA (eicosapentaenoic acid) + 1.15 g DHA (docosahexaenoic acid)/day (10 capsules/day of MAXEPA, Seven Seas U.K.). The lipoproteins were measured using the BIO-LACHEMA kits, the fatty acid spectrum in phospholipids was determined by gas chromatography and prostanoids (after their separation) were measured by RIA methods.

MAIN RESULTS AND CONCLUSIONS:

After the MAXEPA treatment there has been a strong decrease in TG (p < 0.005) and VLDL (p < 0.002) serum levels, accompanied by a significant increase in HDL (p < 0.02). The final-to-baseline TG ratio in individual patients negatively correlated with the relative percentage of EPA in phospholipids after the treatment (p < 0.03; r = -0.474). There was no significant change in serum total cholesterol, fasting glycaemia and glycosylated hemoglobin. There was a slight, but statistically already significant (p < 0.05), rise in LDL. The relative percentage of EPA, docosapentaenoic acid and DHA in serum phospholipids increased sharply (p < 0.001, p < 0.001, p < 0.001). The increase of n-3 PUFA in individual patients was linked with the decrease in n-6 PUFA (p < 0.001; r = -0.686). The spectrum of the latter has changed also very markedly. The prostacyclin PGI2-to-thromboxane TxA2 ratio increased significantly (p < 0.001). Beneficial effects of n-3 fatty acids have prevailed and this kind of treatment seems very encouraging also in NIDDM patients. The results are logically compatible with other authors' results pattern formed in 1990s. A slight rise in serum LDL needs a more detailed discussion since only its phenotype B ("small dense LDL particles") has been recently found to be atherogenic. (Tab. 2, Fig. 5, Ref. 15.)

• Authors: P Habán, R Simoncic, I Klvanová, L Ozdín, E Zideková
• Journal: Bratislavske lekarske listy (Bratisl Lek Listy) Vol. 99 Issue 1 Pg. 37-42 (Jan 1998) ISSN: 0006-9248 [Print] Slovakia
• Vernacular Title: Vplyv podávania n-3 mastných kyselín na vybrané ukazovatele kardiovaskulárnych rizík u pacientov s diabetom mellitus II. typu.
• PMID: 9588078 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cholesterol, HDL
• Cholesterol, VLDL
• Drug Combinations
• Fatty Acids, Omega-3
• Fish Oils
• Maxepa
• Triglycerides
• Docosahexaenoic Acids
• Eicosapentaenoic Acid

Topics

• Cardiovascular Diseases (blood, prevention & control)
• Cholesterol, HDL (blood)
• Cholesterol, VLDL (blood)
• Diabetes Mellitus, Type 2 (complications)
• Docosahexaenoic Acids (therapeutic use)
• Drug Combinations
• Eicosapentaenoic Acid (therapeutic use)
• Fatty Acids, Omega-3 (therapeutic use)
• Female
• Fish Oils (therapeutic use)
• Humans
• Hyperlipoproteinemia Type IV (blood, complications, drug therapy)
• Male
• Middle Aged
• Risk Factors
• Triglycerides (blood)